Skip to main content
Mark Schroeder, MD, Oncology, Saint Louis, MO

MarkAndrewSchroederMD

Oncology Saint Louis, MO

Hematologic Oncology

Assistant Professor of Medicine

Dr. Schroeder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Schroeder's full profile

Already have an account?

  • Office

    4921 Parkview Pl
    # Dv
    Saint Louis, MO 63110
    Phone+1 314-454-8304
    Fax+1 314-454-5902

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
  • University of Cincinnati College of Medicine
    University of Cincinnati College of MedicineClass of 2003

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2018 - 2026
  • MO State Medical License
    MO State Medical License 2006 - 2025
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation  
    M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

  • Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma
    Mark A. Schroeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
    Mark A. Schroeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...
    Mark A. Schroeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • SYNTHETIC BIOLOGICS, INC. MANAGEMENT's DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (Form 10-Q)
    SYNTHETIC BIOLOGICS, INC. MANAGEMENT's DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (Form 10-Q)August 11th, 2022
  • Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft
    Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraftOctober 23rd, 2020
  • St. Louis: One of the Fastest-Growing Life Sciences Markets
    St. Louis: One of the Fastest-Growing Life Sciences MarketsMarch 27th, 2019
  • Join now to see all